品质为先。

     

APAC MARKETS

我们设法促进高度专业化和具有科学价值的领域的发展,以提高医疗保健的标准。

发现更多关于美纳里尼集团的信息

30 多年来,美纳里尼一直致力于推动研发,为受严重健康问题影响的患者提供创新且有效的药物和医疗保健解决方案。

在13个主要市场获取进入亚太地区所有主要市场的单点式入口。

分享您的合作意向

充分利用我们的全渠道方法使您的品牌在亚太地区增长。

MARKETS

亚太地区的医疗行业正在快速增长。美纳里尼亚太隶属于世界领先的意大利生物制药公司,在该地区13个主要市场拥有强大的布局。

作为众多全球医疗保健公司的首选合作伙伴,我们参与整个药品开发生命周期,挖掘增长机会并扩大其品牌影响力。在此过程中,我们还为医务工作者和患者提供优质医疗产品和技术支持,以提高标准并为未来缔造健康生活。

我们的亚太地区总部

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

新闻

2021 - 08 - 22

Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE® in Singapore, Malaysia, and the Philippines

Singapore, 23 August, 2021 - A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the leading Italian global biopharmaceutical company Menarini Group, signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally administered gabapentinoid, mirogabalin (brand name; TARLIGE®), in the Philippines, Malaysia and Singapore.

TARLIGE® was developed and is currently marketed in Japan by Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) and is indicated for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia. The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.

Neuropathic pain, which refers to pain caused by a lesion or disease of the somatosensory nervous system, has been shown to be prevalent in the general population by as much as 7 to 8 percent[1]. Patients with neuropathic pain are more susceptible to high pain intensity with more comorbidities, such as depression panic/anxiety disorder, and sleep disorders[2].

 “The Menarini Group already has an on-going global partnership with Daiichi Sankyo and the partnership on TARLIGE® is another important milestone for us. This is a strategic move to complement our established portfolio of pain products that cover acute to chronic and cancer pain. Menarini Asia-Pacific is committed to helping alleviate pain and delivering treatment solutions to address the unmet needs of patients in this region,” said Maurizio Luongo, CEO of Menarini Asia-Pacific.

 

#####

About Menarini Asia-Pacific

Menarini Asia-Pacific is a member of the Menarini Group, the world’s largest Italian biopharmaceutical company with a heritage of over 130 years and over 17,000 employees in more than 140 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval, and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men’s Health. For the Financial Year 2020, the Menarini Group clocked sales revenues of US 4.6 billion dollars, of which the Asia Pacific region has grown to become a dynamic engine of growth for the Group with more than 10% revenue contribution. 

For more information, visit www.menariniapac.com

 

Media Contact:

Menarini Asia-Pacific Holdings Pte Ltd

Ms. Crystella Lim, Senior Regional Corporate Branding & Communications Manager

Email: crystella.lim@menariniapac.com

Tel: (65) 6494 3427  

 

[1] Didier Bouhassira, Michel Lantéri-Minet, Nadine Attal, Bernard Laurent, Chantal Touboul (2008) Prevalence of chronic pain with neuropathic characteristics in the general population, PAIN, 136:3, 380-387, DOI: j.pain.2007.08.013

[2] Rainer Freynhagen, Ralf Baron, Ulrich Gockel & Thomas R. Tölle (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain, Current Medical Research and Opinion, 22:10, 1911-1920, DOI: 10.1185/030079906X132488

If you'd like to know more about Menarini, feel free to download our PDF files here.